Shandong Sinobioway Biomedicine (002581) Stock Overview

Shandong Sinobioway Biomedicine Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates in China. The company manufactures and supplies trimethyl orthoformate, triethyl orthoformate, trimethyl orthoacetate, phosphorous acid, ethyl formate, and trimethyl acetate and its by-products. It also offers Anfulan, a human interferon a2b injection; Jiefu, a human interferon a2b spray; Enjingfu, a mouse nerve growth factor for injection; and Bellaph, a combined hepatitis A and B vaccine. In addition, the company is involved in biopharmaceutical research and development services, including cell line development and cell bank building, cell culture process development, protein purification process development, preparation prescription and process development, analysis and detection method development, and quality research. Further, it provides biopharmaceutical production services, such as preclinical, clinical phase I/II/III and commercial manufacturing; and other services, including regulatory service support and drug registration affairs. Shandong Sinobioway Biomedicine Co., Ltd. was founded in 2000 and is based in Shenzhen, China. Shandong Sinobioway Biomedicine Co., Ltd. is the subsidiary of Shenzhen Yilian Technology Co., Ltd.